New treatment treats carbon monoxide poisoning in a few minutes

More than 1,500 Americans die of carbon monoxide poisoning (CO) each year and more than 50,000 are looking for emergency treatment.

Jesus Tejero, an Associate Professor of Medicine, and his workshop at the heart of the University of Pittsburgh, the Institute of Spirit, Blood and Vascular Medicine developed the RECC-HBD-CCC, a protein-based treatment for poisoning by CO, with CO, with the Mark Gladwin team.

The RECC-HBD-CCC is administered intravenously in COh wraps of bloodthirsty in the blood, isolating it until the body secretes the co-bonded protein in the urine. Their findings show that the RECOM-HBD-CCC provides a safe, rapid cleansing of CO, which is unmatched by other heME-based therapeutics.

Researchers study the interactions between plateins and their lists, including CO, Oxygen (O2) and nitric oxide (NO), and use or modify them for therapeutic purposes.

RCC, short for the “CO metabolism regulator”, is a CO sensor protein isolated from the bacterium Paraburkholderia xenovorans. These bacteria express the RECC protein to feel nanomatic amounts of CO through the blood -binding field. Once connected to CO with Heme, it activates the other area of ​​the protein, called DNA binding field, to begin the gene expression associated with CO metabolism. Tejero and Gladwin took advantage of this interaction as a potential therapeutic for CO poisoning using only a mechanical version of the HBD sector (HBD), which caused the ROM-HBD-CCC.

When we breathe and fill our lungs with air, hemoglobin in the red blood cells is loaded with oxygen. Then, as the blood circulates through arteries, the oxygen diffuses into tissues and maintains cellular breathing.

On the contrary, it is toxic. This colorless, odorless gas is a by -product of incomplete carbon fountain, such as gasoline, gas and carbon. CO is bound to hemoglobin about 100 times stronger than binding to O2. If we are exposed to CO during a fire, CO steals the “seat” of O2 in hemoglobin and other hemophoric proteins as it circulates through blood circulation. The resulting deprivation of oxygen in the tissues, called hypoxia, leads to symptoms of dizziness, headache, dyspnoea, confusion and/or loss of consciousness.

The faster CO is removed from blood circulation, the better the result will be. GO-TO Treatment for CO poisoning breathes 100% oxygen through mask, which is widely available. In some cases, patients can recover into a hyperbaric oxygen chamber, which incorporates patients, increases atmospheric pressure and provides 100% oxygen. But there are only about 300 facilities that provide it to the United States.

Current treatments certainly reduce CO levels, but it remains difficult to clean, or clean, CO from blood circulation and cells. CO can “bounce” from hemoglobin to other healing in the cell and remove their function, such as those in mitochondria. Exposure to CO can lead to long -term neurological or heart deficits, so that new treatments that isolate and remove CO from circulation and tissues will prevent these harmful effects. RCC is unique in this sense because of its affinity and unparalleled CO specialty compared to other healing.

“If your protein is bound with a very high affinity but binds oxygen, you have so much oxygen in the blood that will [also] Grab oxygen and will compete, “says Tejero.

Using a method called electronic spectroscopy of gradual flow, researchers show that RECC-HBD-CCC binds CO almost 50 times tighter than hemoglobin.

“The affinity of RECC-HBD-CCC for CO is so high. It will bind as soon as it enters the bloodstream, so the limit is how quickly you can enrich the protein and how much,” says Tejero.

The specialization of RECC-HBD-CCC for CO above O2 is also unique. Hemoproteins, such as RECC and hemoglobin, which binds O2 also cleanse not from circulation. No one stimulates angiopes and increases blood flow. Up to this point, intravenous granted hemoproteins purify not and cause the recipient to become hypertensive, which excluded the development of previous hemoglobin -based treatments.

In the preclinical models of researchers, intravenous administration of RECC-HBD-CCC had no hypertensive effect, which is an important finding and a new contribution to the sector. As a test, the researchers were injected hemoglobin, which cheats not.

“[When we infuse hemoglobin]Blood pressure goes up because cheating not, but we see that the injection RECD-HBD-CCC does not increase blood pressure, “says Tejero.

“This was quite important, because when people were trying to invent oxygen carriers based on hemoglobin or artificial blood … they always caused hypertension when they were injected by non -cleansing …. [by the Food and Drug Administration in the United States]. ”

Although still in progress, the unique properties of ROM pave the way for future studies in Tejero’s laboratory.

‘We believe that [nonhypertensive effect] It is very hopeful to use ROM as a basis for the development of artificial oxygen operators … This is the future of this project and we are already working to do it in an oxygen carrier. “

Tejero and his colleagues are intended to increase the recombinant production of ROM-HBD-CCC for Phase I clinical trials.

“We believe that RCC-HBD-CCC [will be] A treatment for CO poisoning … which can be injected as soon as possible …. In ideal, it will be something that is equipped with fire departments or ambulances for quick answers to CO poisoning, “says Tejero.

Tejero and Gladwin are also members of the Board of Directors of Globin Solutions, a Pitt Spit-Off biotechnology company that focuses on the development of CO-poisoning and other medical countermeasures based on technology that have been licensed by PitT and national health institutes.

Findings appear in Proceedings of the National Academy of Sciences.

Source: University of Pittsburgh